These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 15866703)

  • 1. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus.
    Toubi E; Kessel A; Shoenfeld Y
    Hum Immunol; 2005 Apr; 66(4):395-402. PubMed ID: 15866703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Long-term treatment with i.v. immunoglobulin in the therapy of systemic lupus erythematosus].
    Francioni C; Fioravanti A; Gelli R; Megale F; Marcolongo R
    Recenti Prog Med; 1993 Oct; 84(10):679-86. PubMed ID: 8235034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside.
    Zandman-Goddard G; Blank M; Shoenfeld Y
    Lupus; 2009 Sep; 18(10):884-8. PubMed ID: 19671787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immunoglobulin for immunomodulation of systemic lupus erythematosus.
    Sherer Y; Shoenfeld Y
    Autoimmun Rev; 2006 Feb; 5(2):153-5. PubMed ID: 16431350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases.
    Sherer Y; Kuechler S; Jose Scali J; Rovensky J; Levy Y; Zandman-Goddard G; Shoenfeld Y
    Isr Med Assoc J; 2008 Jan; 10(1):55-7. PubMed ID: 18300575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin: report of 2 cases.
    Winder A; Molad Y; Ostfeld I; Kenet G; Pinkhas J; Sidi Y
    J Rheumatol; 1993 Mar; 20(3):495-8. PubMed ID: 8478856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Intravenous administration of immunoglobulins in systemic lupus erythematosus: review of the literature and initial clinical experiences].
    Pirner K; Rubbert A; Burmester GR; Kalden JR; Manger B
    Infusionsther Transfusionsmed; 1993 Apr; 20 Suppl 1():131-5; discussion 136. PubMed ID: 8499742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus.
    Bayry J; Lacroix-Desmazes S; Delignat S; Mouthon L; Weill B; Kazatchkine MD; Kaveri SV
    Arthritis Rheum; 2003 Dec; 48(12):3497-502. PubMed ID: 14674000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [High dose intravenous immunoglobulins in treating systemic lupus erythematosus-associated thrombocytopenia].
    Zhang X; Dong Y; Tang F; Zhang F; Li H
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2000 Feb; 22(1):82-4. PubMed ID: 12903501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous immunoglobulin therapy and systemic lupus erythematosus.
    Zandman-Goddard G; Levy Y; Shoenfeld Y
    Clin Rev Allergy Immunol; 2005 Dec; 29(3):219-28. PubMed ID: 16391397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sugar-free, glycine-stabilized intravenous immunoglobulin prevents skin but not renal disease in the MRL/lpr mouse model of systemic lupus.
    Racz Z; Nagy E; Rosivall L; Szebeni J; Hamar P
    Lupus; 2010 Apr; 19(5):599-612. PubMed ID: 20167630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss.
    Sapir T; Blank M; Shoenfeld Y
    Ann N Y Acad Sci; 2005 Jun; 1051():743-78. PubMed ID: 16127014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of Evans syndrome combined with systemic lupus erythematosus successfully treated with rituximab.
    Kittaka K; Dobashi H; Baba N; Iseki K; Kameda T; Susaki K; Kitanaka A; Kubota Y; Ishida T
    Scand J Rheumatol; 2008; 37(5):390-3. PubMed ID: 18609263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunomodulatory effects of intravenous immunoglobulins].
    Kazatchkine M; Mouthon L; Kaveri SV
    Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S13-8. PubMed ID: 10896983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study.
    Schroeder JO; Zeuner RA; Euler HH; Löffler H
    J Rheumatol; 1996 Jan; 23(1):71-5. PubMed ID: 8838511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
    Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
    J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous immunoglobulin: an emerging treatment for immune-mediated skin diseases.
    Rütter A; Luger TA
    Curr Opin Investig Drugs; 2002 May; 3(5):713-9. PubMed ID: 12090544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous immune globulin in the treatment of patients with systemic lupus erythematosus and end-stage renal disease.
    Becker BN; Fuchs H; Hakim R
    J Am Soc Nephrol; 1995 Apr; 5(10):1746-50. PubMed ID: 7787141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients.
    Shoenfeld Y; Katz U
    Autoimmunity; 2005 Mar; 38(2):123-37. PubMed ID: 16040333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of action of intravenous immune globulin in immune-mediated diseases.
    Mouthon L; Kaveri SV; Spalter SH; Lacroix-Desmazes S; Lefranc C; Desai R; Kazatchkine MD
    Clin Exp Immunol; 1996 May; 104 Suppl 1():3-9. PubMed ID: 8625540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.